Health News

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) wi...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation macrophage-directed immunotherapies for cancer, today announced it will host an educational webinar on Monday, August 10, 2026 from 12:00 p.m. – 2:00 p.m. ET. The webinar will focus on the emerging role of macrophage checkpoint biology for the treatment of solid tumors as well as Pheast’s lead program, PHST001, a novel, high-affinity IgG4 anti-CD24 monoclonal antibody curr...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial...

MELBOURNE, Australia--(BUSINESS WIRE)--STRONG Pilates, the global fitness franchise combining Pilates, cardio and strength training, today announced a Master Franchise partnership with Poland's leading wellness franchise operator, Xtreme Brands, to drive expansion across Central and Eastern Europe. The agreement marks STRONG Pilates' entry into Poland and the Czech Republic and expands the brand's global footprint to 16 countries, including the U.S., Australia, New Zealand, Canada, the UK, Irel...

NAPA, Calif.--(BUSINESS WIRE)--28th Annual V Foundation for Cancer Research Wine Celebration Raises Nearly $7 Million to Accelerate Breakthrough Cancer Research...

DALLAS--(BUSINESS WIRE)--Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in communities and services for seniors, announced today that it will issue its second quarter 2026 earnings results before the market opens for trading on Monday, August 10, 2026. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time. The dial-in number for the conference call...

SAN DIEGO--(BUSINESS WIRE)--Inocras Closes $31 Million in Oversubscribed Series B-3 Financing to Accelerate U.S. Commercial Expansion....

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning c...